Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin and N-acetylcysteine for prevention of colistin-associated nephrotoxicity
IRCT20150221021159N3Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of melatonin, acetylcysteine and colistin in acute kidney failure (AKF) (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Urinary neutrophil gelatinase-associated lipocalin level and Serum creatinine level. Started Dec 2018; status: completed.
02
Drugs
melatoninacetylcysteinecolistin
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on IRCT20150221021159N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150221021159N3.